<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997252</url>
  </required_header>
  <id_info>
    <org_study_id>Chen-001</org_study_id>
    <nct_id>NCT04997252</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer</brief_title>
  <official_title>An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The neoadjuvant therapy with apalutamide can significantly improve the prognosis of patients&#xD;
      with high-risk and oligometastatic prostate cancer, lower the rate of positive margins,&#xD;
      reduce recurrence, and show high safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rPFS</measure>
    <time_frame>Change from Baseline at preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
    <description>radiographic progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR</measure>
    <time_frame>preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
    <description>pathological complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
    <description>positive margin rate; progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate:</measure>
    <time_frame>preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
    <description>more than 50% decrease from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTPP</measure>
    <time_frame>preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
    <description>time to PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to BCR after surgery</measure>
    <time_frame>preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological stage</measure>
    <time_frame>preoperative 1, 2, and 3 months and postoperative 1, 3, 6, 9, 12, 18, and 24 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>High-Risk and Oligometastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>high-risk and oligometastatic prostate cance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy with apalutamide in combination with luteinizing hormone-releasing hormone analogues</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>apalutamide as neoadjuvant therapy</description>
    <arm_group_label>high-risk and oligometastatic prostate cance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males aged above 18 years old, no healthy volunteers included;&#xD;
&#xD;
          2. Prostate cancer confirmed by pathological findings;&#xD;
&#xD;
          3. High risk based on risk assessment, or laboratory tests suggestive of oligometastasis;&#xD;
&#xD;
          4. Agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy;&#xD;
&#xD;
          5. ECOG score of 0 - 1&#xD;
&#xD;
          6. Agreement to undergo preoperative and postoperative endocrine therapy;&#xD;
&#xD;
          7. Voluntary signing of an ICF for the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other tumor disease requiring treatment;&#xD;
&#xD;
          2. Any organ metastasis confirmed by imaging, such as liver and brain metastases, or the&#xD;
             possibility of paralysis due to spinal cord metastasis;&#xD;
&#xD;
          3. A history of epilepsy or any condition that may lead to seizures;&#xD;
&#xD;
          4. Severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases,&#xD;
             and systemic immune system diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang yiming</last_name>
    <phone>020-62782726</phone>
    <email>59281481@qq.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhujiang Hospital</investigator_affiliation>
    <investigator_full_name>Binshen Chen</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

